Transplant patients experience less pain and fewer adverse events with caredx non-invasive testing solutions

Brisbane, calif.--(business wire)--caredx, inc. (nasdaq: cdna) – the transplant company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a new peer-reviewed publication showing that allomap®, the industry's only gene-expression profiling (gep) blood test to non-invasively assess graft rejection by monitoring immune quiescence in heart transplant patients,1 resulted
CDNA Ratings Summary
CDNA Quant Ranking